The news of JMP Securities reiterating a Market Outperform rating and maintaining a $15 price target on Allogene Therapeutics is positive for the company's stock. This reaffirms the analyst's confidence in the company's performance and potential growth, which could lead to an increase in investor interest and a short-term positive impact on the stock price.